Lumiradx receives approval for its covid-19 antigen test for use in india

London, oct. 20, 2021 /prnewswire/ -- today, lumiradx (nasdaq: lmdx), a next-generation point of care diagnostics testing company announced it has received emergency use approval by india's central drugs standard control organisation for its sars-cov-2 antigen test for use in india. the test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
LMDX Ratings Summary
LMDX Quant Ranking